SCHEMBL7089136

SCHEMBL7089136

COc1c(C)cc(C(=O)O)c(C)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.46
TDP1 Q9NUW8 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 3/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
PKM P14618 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 4/20 0.40
TPMT P51580 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
GFER P55789 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MYC P01106 1/20 0.38
NOTUM Q6P988 1/20 0.38
AKR1C3 P42330 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15573104 0.88 HSD17B10 (0.46) HSD17B10TDP1MAPTKDM4EMEN1
SCHEMBL31012417 0.88 HSD17B10 (0.46) HSD17B10TDP1MAPTKDM4EMEN1
SCHEMBL4303369 0.86 HSD17B10 (0.44) HSD17B10TDP1MAPTKDM4EMEN1
SCHEMBL14124075 0.85 MAPT (0.47) HSD17B10TDP1MAPTKDM4EMEN1
SCHEMBL28887578 0.85 HSD17B10 (0.43) HSD17B10TDP1MAPTKDM4EMEN1
SCHEMBL29173808 0.82 KDM4E (0.46) HSD17B10MAPTKDM4EHPGDGAA
SCHEMBL1434189 0.82 HSD17B10 (0.52) HSD17B10TDP1MAPTKDM4EHPGD
Carbamic Acid SCHEMBL30873816 0.80 KDM4E (0.45) HSD17B10MAPTKDM4EHPGDGAA
SCHEMBL9720645 0.79 ALDH1A1 (0.51) HSD17B10MAPTKDM4EMEN1KMT2A
SCHEMBL11928780 0.79 KDM4E (0.41) HSD17B10TDP1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228811-A1 Triester Compounds And Methods Of Use Thereof LIFEMINE THERAPEUTICS, INC. 2025-07-17 US disclosed
WO-2025137071-A2 TRIESTER COMPOUNDS AND METHODS OF USE THEREOF LIFEMINE THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
CN-106661018-B Pyrrolo- [2,3-C] pyridine as neurofibrillary tangles imaging agent 默沙东公司 2019-07-19 CN disclosed
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 HSD17B10 184/4885TDP1 4424/4885MAPT 4666/4885
US-20250228811-A1 Triester Compounds And Methods Of Use Thereof CYP46A1, CYP17A1, CYP27A1 HSD17B10 45/4885TDP1 1071/4885MAPT 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.